Search | Clinical Trials Finder

Conditions: Pyoderma Gangrenosum
Interventions: Spesolimab, Placebo matching to spesolimab, Prednisone, Prednisolone; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 23 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: GLPG1690, Placebo; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 40 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 47
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 42 more

Conditions: Drug-Resistant Epilepsy, Focal-Onset Seizures
Interventions: Padsevonil, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 32
States / cities: Chandler, Arizona • Tucson, Arizona • Carlsbad, California + 29 more

Conditions: Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Interventions: Vicadrostat, Empagliflozin, Placebo matching Vicadrostat; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 11,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 210
States / cities: Anniston, Alabama • Fairhope, Alabama • Guntersville, Alabama + 173 more

Conditions: Opioid Use Disorder
Interventions: BI 1356225, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Los Alamitos, California • Los Angeles, California • Decatur, Georgia + 2 more

Conditions: Respiratory Disease
Interventions: respiratory pathogen panel; Other
Lead sponsor: Data Collection Analysis Business Management; Other
Eligibility: 18 Years to 64 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Land O' Lakes, Florida

Conditions: Asthma
Interventions: TEV-56248, Albuterol sulfate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 4 Years and older
Enrollment: 2,772 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 157
States / cities: Birmingham, Alabama • Dothan, Alabama • Paradise Valley, Arizona + 113 more

Conditions: Obesity
Interventions: Survodutide, Semaglutide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Orlando, Florida • Baton Rouge, Louisiana

Conditions: Ankylosing Spondylitis
Interventions: Bimekizumab, Certolizumab pegol, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Ormond Beach, Florida • Lincoln, Nebraska • Oklahoma City, Oklahoma + 1 more

Conditions: Dermatitis, Contact
Interventions: T.R.U.E. Test; Biological
Lead sponsor: Allerderm; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Lung Transplant Rejection
Interventions: Belumosudil, Azithromycin, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more

Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions: Ralinepag; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 48
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more

Conditions: Myocardial Infarction
Interventions: Empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 6,522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 85
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 75 more

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: Survodutide, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 36
States / cities: Huntsville, Alabama • Coronado, California • Huntington Park, California + 31 more

Conditions: Heart Failure
Interventions: vicadrostat, empagliflozin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 91
States / cities: Beverly Hills, California • Covina, California • Encinitas, California + 77 more

Conditions: Colitis, Ulcerative
Interventions: Golimumab; Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 15
States / cities: La Jolla, California • National City, California • Denver, Colorado + 12 more

Conditions: Cystic Fibrosis
Interventions: BI 1265162, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: Orlando, Florida • Indianapolis, Indiana • Chapel Hill, North Carolina + 5 more

Conditions: Contact Dermatitis
Interventions: Patch Test; Biological
Lead sponsor: Allerderm; Industry
Eligibility: 6 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Aurora, Colorado • Louisville, Kentucky

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BI 1015550, Pirfenidone; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: The Woodlands, Texas

Conditions: Brain Injury, Dementia, Healthy, Mental Disorder, Schizophrenia
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 810 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1992 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C, Substance Use Disorders
Interventions: HCV GET-Up (Group Evaluation and Treatment Uptake); Behavioral
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Strep Throat
Interventions: Not listed
Lead sponsor: IND Diagnostic Inc.; Industry
Eligibility: 3 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Bellevue, Nebraska • Franklin, Tennessee • Smyrna, Tennessee

Conditions: Depressive Disorder, Major
Interventions: BI 1358894, Placebo, Quetiapine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 29
States / cities: Birmingham, Alabama • Garden Grove, California • Long Beach, California + 23 more

Conditions: Allergic Contact Dermatitis
Interventions: Panels 1.3, 2.2 and 3.2 experimental allergens; Diagnostic Test
Lead sponsor: Allerderm; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: San Diego, California • Aurora, Colorado • Louisville, Kentucky + 1 more

Search by objective public record fields.

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine

How Respiratory Pathogens Panel Results Affect Patients' Plan of Care

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

Clinical Evaluation of T.R.U.E. TEST in Children and Adolescents

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

Neuropsychiatric Evaluation of Healthy Volunteers and Adults With Schizophrenia

HCV Group Evaluation and Treatment Uptake (HCV GET-UP) Intervention

Evaluation of the IND One Step Strep A Rapid Test vs. Culture

A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression

Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents